NASDAQ:KTOV - KITOV PHARMA LT/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.14 +0.01 (+0.88 %)
(As of 02/19/2019 04:00 PM ET)
Previous Close$1.13
Today's Range$1.12 - $1.15
52-Week Range$0.56 - $3.81
Volume2,116 shs
Average Volume3.70 million shs
Market Capitalization$17.96 million
P/E Ratio2.92
Dividend YieldN/A
Beta4.55
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study. It is also developing NT219, a small molecule that targets two pathways involved in cancer drug resistance. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. Kitov Pharma Ltd was founded in 2010 and is headquartered in Tel Aviv, Israel.

Receive KTOV News and Ratings via Email

Sign-up to receive the latest news and ratings for KTOV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KTOV
CUSIPN/A
Phone972-3933-3121

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1 million
Cash Flow$0.3476 per share
Book Value$0.70 per share

Profitability

Miscellaneous

Employees1
Market Cap$17.96 million
OptionableNot Optionable

KITOV PHARMA LT/S (NASDAQ:KTOV) Frequently Asked Questions

What is KITOV PHARMA LT/S's stock symbol?

KITOV PHARMA LT/S trades on the NASDAQ under the ticker symbol "KTOV."

When is KITOV PHARMA LT/S's next earnings date?

KITOV PHARMA LT/S is scheduled to release their next quarterly earnings announcement on Monday, March 4th 2019. View Earnings Estimates for KITOV PHARMA LT/S.

What price target have analysts set for KTOV?

1 equities research analysts have issued 1 year target prices for KITOV PHARMA LT/S's stock. Their predictions range from $12.50 to $12.50. On average, they anticipate KITOV PHARMA LT/S's stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 996.5% from the stock's current price. View Analyst Price Targets for KITOV PHARMA LT/S.

What is the consensus analysts' recommendation for KITOV PHARMA LT/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KITOV PHARMA LT/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for KITOV PHARMA LT/S.

What are Wall Street analysts saying about KITOV PHARMA LT/S stock?

Here are some recent quotes from research analysts about KITOV PHARMA LT/S stock:
  • 1. According to Zacks Investment Research, "Kitov Pharmaceuticals Holdings Ltd. is a pharmaceutical company which focused on the development of therapeutic candidates. The company's product candidate consists of KIT-302, is formulated for treatment of pain caused by osteoarthritis and hypertension, which can be pre-existing or caused by the treatment for OA. Kitov Pharmaceuticals Holdings Ltd. is based in Jerusalem, Israel. " (6/15/2018)
  • 2. HC Wainwright analysts commented, "We remind investors that KIT-302, a combination drug intended to simultaneously treat osteoarthritis-related pain and hypertension (a common side effect of stand-alone drugs that treat osteoarthritis-related pain), is comprised of two FDA-approved drugs, celecoxib (Celebrex®), a non-steroidal anti-inflammatory COX-2 inhibitor (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc®), a calcium channel blocker for lowering blood pressure. The approval decision date for KIT-302 is May 31, 2018. We consider the China licensing transaction to be evidence that Kitov is continuing to pursue initiatives to optimize the commercial value of its lead candidate, and remain confident that Consensi should be approved by the end of this month. We reiterate our Buy rating and 12-month price target of $10.00 per share." (5/14/2018)

Has KITOV PHARMA LT/S been receiving favorable news coverage?

Press coverage about KTOV stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. KITOV PHARMA LT/S earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are some of KITOV PHARMA LT/S's key competitors?

Who are KITOV PHARMA LT/S's key executives?

KITOV PHARMA LT/S's management team includes the folowing people:
  • Dr. John Paul Waymack, Founder, Chairman & Chief Medical Officer (Age 67)
  • Mr. Isaac Israel, CEO & Director (Age 41)
  • Dr. Hadas Reuveni, Founder & CTO of TyrNovo (Age 52)
  • Dr. Gil Ben-Menachem MSc, MBA, Ph.D., VP of Bus. Devel. & Director (Age 52)
  • Mr. Simcha Rock CPA, MBA, Strategic Advisor & Director (Age 69)

When did KITOV PHARMA LT/S IPO?

(KTOV) raised $13 million in an initial public offering (IPO) on Friday, November 20th 2015. The company issued 3,200,000 shares at $4.13 per share. Rodman & Renshaw (a unit of H.C. Wainwright & Co.,) and Joseph Gunnar acted as the underwriters for the IPO.

How do I buy shares of KITOV PHARMA LT/S?

Shares of KTOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is KITOV PHARMA LT/S's stock price today?

One share of KTOV stock can currently be purchased for approximately $1.14.

How big of a company is KITOV PHARMA LT/S?

KITOV PHARMA LT/S has a market capitalization of $17.96 million and generates $1 million in revenue each year. The company earns $-5,200,000.00 in net income (profit) each year or $0.39 on an earnings per share basis. KITOV PHARMA LT/S employs 1 workers across the globe.

What is KITOV PHARMA LT/S's official website?

The official website for KITOV PHARMA LT/S is http://www.kitovpharma.com.

How can I contact KITOV PHARMA LT/S?

KITOV PHARMA LT/S's mailing address is One Azrieli Center Round Tower 132 Menachem Begin Road, Tel Aviv L3, 6701101. The company can be reached via phone at 972-3933-3121.


MarketBeat Community Rating for KITOV PHARMA LT/S (NASDAQ KTOV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  215
MarketBeat's community ratings are surveys of what our community members think about KITOV PHARMA LT/S and other stocks. Vote "Outperform" if you believe KTOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KTOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Featured Article: Strangles

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel